738
J. Zhong et al. / Tetrahedron: Asymmetry 18 (2007) 734–741
4.3.1.
(1R,3S)-Methyl
2,2-dimethyl-3-((pyrrolidin-1-
(500 MHz, CDCl3): d 0.91 (s, 3H), 0.92–1.02 (m, 1H),
18
yl)-methyl)cyclopropanecarboxylate 7a. Dense oil, ½aꢂD
ꢀ4:3 (c 1.62, EtOH); IR (neat) 2952, 2782, 1729, 1437,
1383, 1355, 1175, 1140, 1088, 852 cmꢀ1 1H NMR
(500 MHz, CDCl3): d 1.19 (s, 3H), 1.23 (s, 3H), 1.30–1.34
(br s, 4H), 1.53 (d, 1H, J = 9.0 Hz), 1.77 (br s, 4H), 2.52
(br s, 1H), 2.71–2.75 (m, 1H), 2.85–2.89 (m, 1H), 3.64 (s,
3H); 13C NMR (125 MHz, CDCl3): d 14.5, 23.4, 25.1,
28.5, 28.7, 32.4, 50.0, 51.1, 53.9, 172.2; HRMS (TOF):
m/z calcd for C12H22NO2 [M+H]+: 212.1651, found:
212.1642.
¼
1.22 (s, 3H), 1.61–1.64 (m, 2H), 1.65–1.74 (m, 3H), 2.40–
2.91 (m, 5H), 2.93–2.95 (m, 1H), 7.09–7.16 (m, 2H),
7.22–7.28 (m, 4H), 7.50–7.56 (m, 4H), 8.09(br s, 1H); 13C
NMR (125 MHz, CDCl3): d 15.5, 20.1, 23.3, 26.5, 30.1,
38.3, 51.3, 52.9, 125.3, 125.7, 125.9, 127.6, 127.7, 149.1,
152.1; HRMS (TOF): m/z calcd for C23H30NO [M+H]+:
336.2327, found: 336.2322.
;
4.4.2.
((1R,3S)-2,2-Dimethyl-3-((piperidin-1-yl)methyl)-
cyclopropyl)diphenylmethanol 8b. Colorless needles, mp
18
162–163 ꢁC; ½aꢂD ¼ þ167:6 (c 0.82, CHCl3); IR (KBr)
4.3.2.
yl)-methyl)cyclopropanecarboxylate 7b. Dense oil, ½aꢂD
ꢀ7:1 (c 0.98, CHCl3); IR (neat) 2935, 2854, 1729, 1437,
1375, 1174, 1153, 1133, 1089, 849 cmꢀ1 1H NMR
(500 MHz, CDCl3): d 1.18 (s, 3H), 1.21 (s, 3H), 1.26–1.28
(m, 1H), 1.43 (br s, 2H), 1.52 (d, 1H, J = 9.0 Hz), 1.58
(br s, 4H), 2.40 (br s, 4H), 2.58–2.62 (m, 1H), 2.71–2.74
(m, 1H), 3.63 (s, 3H); 13C NMR (125 MHz, CDCl3): d
14.5, 24.4, 25.0, 26.1, 28.5, 28.7, 31.3, 51.1, 53.3, 54.2,
172.1; HRMS (TOF): m/z calcd for C13H24NO2 [M+H]+:
226.1807, found: 226.1810.
(1R,3S)-Methyl
2,2-dimethyl-3-((piperidin-1-
18
3420, 2937, 1444, 1370, 1305, 1194, 1124, 1097, 1062,
¼
1
1028, 1010, 985, 881, 773, 750, 700, 636 cmꢀ1; H NMR
(500 MHz, CDCl3): d 0.89 (s, 3H), 1.00–1.05 (m, 1H),
1.16 (s, 3H), 1.20–1.37 (m, 6H), 1.84 (d, 1H, J = 9.0 Hz),
2.46–2.61 (m, 6H), 7.09–7.14 (m, 2H), 7.22–7.26 (m, 4H),
7.52–7.60 (m, 4H), 7.78 (br s, 1H); 13C NMR (125 MHz,
CDCl3): d 15.4, 20.0, 24.1, 25.1, 25.3, 30.3, 37.3, 53.5,
54.7, 125.63, 125.66, 125.74, 127.5, 127.8, 149.3, 151.9;
HRMS (TOF): m/z calcd for C24H32NO [M+H]+:
350.2484, found: 350.2479.
;
4.3.3. (1R,3S)-Methyl 2,2-dimethyl-3-(morpholinomethyl)-
4.4.3.
((1R,3S)-2,2-Dimethyl-3-(morpholinomethyl)cyclo-
18
cyclopropanecarboxylate 7c. Dense oil, ½aꢂD ¼ þ15:4 (c
propyl)diphenylmethanol 8c. Colorless needles, mp 156–
18
0.88, CHCl3); IR (neat) 2952, 2854, 1727, 1456, 1374,
157 ꢁC; ½aꢂD ¼ þ158:5 (c 0.93, CHCl3); IR (KBr) 3430,
1
1177, 1117, 1087, 1010, 866 cmꢀ1; H NMR (500 MHz,
2822, 1449, 1371, 1299, 1272, 1192, 1113, 1070, 1031,
1014, 920, 864, 778, 752, 706, 637 cmꢀ1
;
1H NMR
CDCl3): d 1.18 (s, 3H), 1.22 (s, 3H), 1.24–1.27 (m, 1H),
1.54 (d, 1H, J = 9.0 Hz), 2.47 (br s, 4H), 2.64–2.68 (m,
1H), 2.74–2.78 (m, 1H), 3.64 (s, 3H), 3.70 (br s, 4H); 13C
NMR (125 MHz, CDCl3): d 14.5, 25.0, 28.4, 28.7, 30.7,
51.1, 52.9, 53.4, 67.1, 172.0; HRMS (TOF): m/z calcd for
C12H22NO3 [M+H]+: 228.1600, found: 228.1589.
(500 MHz, CDCl3): d 0.94 (s, 3H), 0.93–1.05 (m, 1H),
1.17 (s, 3H), 1.88 (d, 1H, J = 9.0 Hz), 2.35 (br s, 2H),
2.52 (br s, 2H), 2.56–2.60 (m, 1H), 2.65–2.69 (m, 2H),
3.30 (b, 2H), 3.48–3.52 (m, 2H), 7.11–7.15 (m, 2H), 7.24–
7.27 (m, 4H), 7.51–7.61 (m, 4H); 13C NMR (125 MHz,
CDCl3): d 15.3, 20.1, 24.5, 30.3, 37.1, 52.6, 54.6, 66.2,
125.4, 125.6, 125.8, 126.2, 127.7, 127.9, 148.9, 151.6;
HRMS (TOF): m/z calcd for C23H30NO2 [M+H]+:
352.2277, found: 352.2272.
4.4. General procedure for the synthesis of cis-cyclopropane
aminoalcohol 8a–c
Magnesium (0.6 g, 25.0 mmol) was added to 20 mL of
anhydrous THF. A solution of bromobenzene (3.14 g,
20 mmol in 10 mL of THF) was added dropwise into the
above mixture. Once the reaction began, the rest of the
bromobenzene solution was added at a rate that main-
tained a gentle reflux. When the addition of the bromobenz-
ene solution was complete, the mixture was refluxed for
20 min, and was then cooled to ꢀ15 ꢁC. Compound 7
(5 mmol) was dissolved in 5 mL of anhydrous THF and
added to the prepared Grignard mixture. After the solution
of compound 7 had been added, the resulting mixture was
stirred at room temperature for an additional 12 h. The
reaction was quenched with saturated NH4Cl (aq), and
the mixture was extracted several times with Et2O. The or-
ganic phases were combined, dried over MgSO4 and con-
centrated under reduced pressure. The residual yellow
solid was purified by flash chromatography (hexane/ethyl
acetate = 1/2) to yield 9a–b as colorless crystals.
4.5. X-ray crystal structure data for (1R,3S)-8b and 8c
Compound 8b: C24H31NO, Mr = 349.50, triclinic, P1,
˚
a = 6.1917(12), b = 8.8540(18), c = 9.7155(19) A; a =
92.53(3)ꢁ,
b = 95.90(3)ꢁ,
c = 105.29(3)ꢁ;
V =
3
˚
509.63(17) A ; 2.39ꢁ < 2h < 27.64ꢁ;
q
calc = 1.273 g cmꢀ3
,
Z = 1, F(000) = 190; Final R1 = 0.0524, wR2 = 0.1447,
all data, R1 = 0.0642, wR2 = 0.1550.
Compound 8c: C23H29NO2, Mr = 351.47, triclinic, P1,
˚
a = 6.2009(12), b = 8.7144(17), c = 9.6164(19) A; a =
92.38(3)ꢁ,
b = 98.64(3)ꢁ,
c = 104.91(3)ꢁ;
V =
3
˚
494.70(17) A ; 2.15ꢁ < 2h < 27.45ꢁ;
q
calc = 1.180 g cmꢀ3
,
Z = 1, F(000) = 190; Final R1 = 0.0473, wR2 = 0.1270,
all data, R1 = 0.0712, wR2 = 0.1398.
CCDC-618048 and CCDC-618049 contain the supplemen-
tary crystallographic data for 8b and 8c, respectively. These
bridge, CB21EZ, UK; fax: (+44)-1223–336–033; or e-mail:
deposit@ccdc.cam.ac.uk].
4.4.1.
((1R,3S)-2,2-Dimethyl-3-((pyrrolidin-1-yl)methyl)-
cyclopropyl)diphenylmethanol 8a. Colorless needles, mp
18
112–113 ꢁC; ½aꢂD ¼ þ14:1 (c 1.51, CHCl3); IR (KBr)
3370, 2949, 1446, 1371, 1346, 1319, 1278, 1184, 1090,
1066, 1032, 956, 876, 768, 748, 700, 636 cmꢀ1; H NMR
1